Padlock Therapeutics is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock is based in Cambridge, MA.
Padlock Therapeutics, a biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, today announced the appointment of Kerri Mowen, Ph.D., one of
2015/11/02Doctors have long treated autoimmune diseases such as arthritis and lupus as a case of a confused immune system: Immune cells decide healthy tissue looks foreign and wage an attack.
2015/10/27Veteran deal-maker and company-builder provides extensive corporate leadership and operational experience as Padlock expands its team and advances multiple programs
Padlock Therapeutics Named by FierceBiotech as a 2015 “Fierce15” Biotech Company
Creates Industry - Leading R&D Effort Focused on Creating PAD Inhibitors for the Treatment of Autoimmune Diseases ...
Company strengthens its position as a leader in developing new treatments for autoimmune disease focus ed on protein citrullination ...
Institutions to Conduct Disease - Specific Pre-clinical Studies With the Company’s Proprietary Investigational Compounds ...
Evotec AG and Padlock Therapeutics, Inc. (“Padlock”) announced today that they have successfully completed an initial goal ...